Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the board previously voted to enforce an upper payment limit on Amgen’s Enbrel in the state, Johnson & Johnson’s Stelara could be next in line.

During its June 7 meeting, the board’s five members unanimously voted that Stelara’s use under its current labeling is “unaffordable” for Colorado consumers. The vote paves the way for an upcoming decision on whether the group will favor setting an upper payment limit on the medicine.